Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared ...
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' next-generation treatment for a rare and ...
The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
(MENAFN- EIN Presswire) Numerous companies, such as Vertex Pharmaceuticals, Eloxx Pharmaceuticals, and others, are actively developing treatments in the Cystic Fibrosis market. LAS VEGAS ...
Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, ...